Wolverine Stack Dosing Guide: BPC-157 + TB-500 Protocol (2026)

The Wolverine Stack is a community shorthand for pairing two research peptides — BPC-157 and TB-500 — into one tissue-repair-focused protocol. The name is borrowed from the comic-book character known for fast healing; it is not a clinical designation and not an FDA-approved treatment.

BPC-157 is studied for local tissue effects: angiogenesis at the injury site, growth-factor signaling, and tendon-bone interface healing in animal models. TB-500 is a fragment of Thymosin Beta-4 and is studied for systemic effects: cell migration, anti-inflammatory signaling, and progenitor-cell mobilization. The stack rationale is that the two compounds cover non-overlapping pieces of the same problem.

Two formats dominate research planning: a pre-blended 1:1 vial (most common is 20 mg total, 10 mg of each compound) dosed daily, or two separate vials dosed on different schedules — daily BPC-157 with twice-weekly TB-500 loading. This guide covers both. For unit math, see the PepPal reconstitution calculator.

This page is for Wolverine Stack steps, timing, and supplies. Want the wider research view? Visit the Wolverine Stack research guide. It covers each peptide, studies, safety notes, and legal status.

Two dosing models dominate Wolverine Stack research planning. The Pre-blended Vial is typically a 1:1 BPC-157 + TB-500 mixture, drawn as a single daily dose. Separate Vials lets BPC-157 and TB-500 run on independent schedules — daily BPC-157 with twice-weekly TB-500 loading. The choice usually comes down to whether independent dose control matters more than convenience.

Both formats deliver the same two compounds. The choice changes how much control there is over each compound's dose and schedule, and how much injection-site management is needed.

The featured math assumes a pre-blended 20 mg vial containing 10 mg BPC-157 plus 10 mg TB-500. Separate-vial planning can still use 10 mg of each compound, but those vials must be tracked independently. The PepPal reconstitution calculator handles unit math for any vial size.

1. Allow lyophilized peptide to reach room temperature. 2. Wipe both vial stoppers (peptide and BAC water) with alcohol swabs. 3. Draw the planned volume of BAC water into a sterile syringe. 4. Inject the BAC water against the inside wall of the peptide vial — slowly, never directly onto the powder. 5. Swirl gently until fully dissolved; do not shake. 6. Verify the solution is clear (TB-500 may appear very faintly tinted). 7. Refrigerate (35.6–46.4°F / 2–8°C) and use within the supplier's stated beyond-use window.

The stack rationale is mechanistic complementarity. BPC-157 and TB-500 both promote tissue repair, but through largely non-overlapping pathways. Pairing them is hypothesized — not proven — to give broader coverage than either alone.

BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. Animal-model evidence consistently shows local effects: angiogenesis at the injury site (VEGF upregulation), growth-factor signaling (EGF, FGF), nitric oxide pathway modulation, and accelerated tendon-to-bone interface healing in rat Achilles transection studies.

TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino-acid actin-binding protein. The parent molecule has Phase 2 human data in cardiac and ocular contexts. Mechanistically, it acts systemically: it sequesters G-actin, promotes endothelial cell migration in scratch-wound assays, and has shown progenitor-cell mobilization signals in preclinical cardiac models.

There is no published human safety data for the Wolverine Stack as a combination. Compound-level data is summarized below, separated from theoretical and quality-control concerns.

BPC-157. Animal studies have reported low acute toxicity. The Vasireddi et al. 2025 systematic review notes the most-cited human exposure as a small open-label knee-pain case series in which 7 of 12 subjects reported pain relief lasting more than 6 months after one intra-articular BPC-157 injection; no serious adverse events were reported. There is no published RCT and no long-term human safety data.

TB-500 (Thymosin Beta-4 fragment). Phase 2 human trials of full-length Thymosin Beta-4 in pressure ulcers and venous stasis ulcers reported no significant adverse events distinguishable from placebo. The TB-500 fragment specifically has not completed a published RCT. Anecdotal reports include mild lethargy or head-pressure during loading phases, but these are not RCT-verified.

Both compounds promote angiogenesis, which is the intended mechanism for repair but is also a relevant pathway in tumor growth. A 2003 J Natl Cancer Inst paper by Cha et al. reported that Thymosin Beta-4 expression increased lung-tumor metastasis in a B16-F10 mouse model. The translational meaning for an exogenous TB-500 fragment in humans is unknown, but it is the most-cited theoretical risk in clinician reviews of this stack and is one reason researchers exclude individuals with active or undiagnosed cancer from any informal protocol.

Reported injection-site issues include redness, mild swelling, transient bruising, and occasional sterile abscess. Most are attributable to technique rather than the peptide. Quality control is the larger practical risk. Independent third-party testing (e.g., Finnrick reports referenced on PepPal supplier pages) has shown variable purity, residual solvents, and endotoxin contamination across grey-market suppliers. Use COA-verified sources.

Both BPC-157 and TB-500 are prohibited under WADA's S0 Unapproved Substances category, in and out of competition. Athletes subject to WADA, USADA, or any sport-governing-body testing program should not assume a clearance window — the substances are detectable and prohibited regardless of timing.

There is no direct clinical evidence for the Wolverine Stack as a combination. No published trial — preclinical or human — has tested BPC-157 + TB-500 together. All clinical context comes from compound-level research.

The Vasireddi et al. 2025 systematic review in HSS Journal screened the full BPC-157 musculoskeletal literature through June 2024 and found a large preclinical base — tendon, ligament, muscle, bone, and nerve injury models — but only one published human exposure dataset, the small open-label knee-pain case series. Foundational tendon-bone work includes Krivic et al. 2006 (Achilles detachment in rat, J Orthop Res) and Chang et al. 2011 (tendon outgrowth and migration, J Appl Physiol). Wound-healing and gut work is reviewed in Seiwerth et al. 2021 (Front Vet Sci).

Most TB-500 mechanism work is on the parent molecule Thymosin Beta-4. Foundational studies include Malinda et al. 1997 (FASEB J) showing endothelial cell migration in scratch-wound assays, and Smart et al. 2007 (Angiogenesis) reviewing angiogenic mechanism. The Tβ4 parent molecule has Phase 2 trial data in pressure-ulcer and venous-ulcer indications. The TB-500 fragment specifically has not completed a published RCT.

Compound-level evidence does not validate the combination. A coherent mechanistic rationale is not the same as demonstrated synergy, and animal-model effect sizes do not translate cleanly to human dosing. Treat any community-derived Wolverine schedule as a research-planning structure, not as evidence of effect.

Neither BPC-157 nor TB-500 is FDA-approved as of May 2026. Both compounds were on the FDA's 503A Category 2 list — substances raising significant safety concerns and effectively blocked from compounding pharmacies — until April 22, 2026.

On April 15, 2026, the FDA published a 503A category revision removing 12 peptides from Category 2 effective seven calendar days later (April 22). BPC-157 and TB-500 were both included. The removal happened because the original nominators voluntarily withdrew their nominations — it is not an FDA determination that these compounds are safe or approved for compounding.

The FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23, 2026 to evaluate BPC-157 and TB-500 (free base and acetate forms), along with KPV and MOTs-C. PCAC will discuss inclusion on the 503A Bulks List. A vote at PCAC is a recommendation to FDA, not a final determination — a final 503A bulks-list decision typically follows weeks-to-months later.

Until PCAC recommends and FDA acts, neither compound is approved for compounding under 503A as a Category 1 substance. Research-chemical channels remain unregulated; compounding pharmacies may not yet legally compound these substances without further FDA action. WADA's S0 prohibition is unaffected by the FDA timeline.

Related research protocols on PDP that come up alongside Wolverine stack planning:

This stack is usually discussed around tissue repair and connective-tissue stress, but labs may not capture local tendon, ligament, or joint response. Monitoring is mainly a broad safety screen plus inflammation context when symptoms suggest it.